Pay vs Performance Disclosure - USD ($)

12 Months Ended

Dec. 31, 2025

Dec. 31, 2024

Dec. 31, 2023

Dec. 31, 2022

Dec. 31, 2021

The following table shows the relationship between executive compensation actually paid to our Principal Executive Officer (“PEO”) and other NEOs, including our Chief Financial Officer, Chief Scientific Officer and Laboratory Director, and President and Chief Operating Officer (“Non-PEO NEOs”), and certain financial performance of the Company during the last five fiscal years ended December 31, 2025, 2024, 2023, 2022, and 2021.


Year	Summary Compensation Table Total for PEO		Compensation Actually Paid to PEO		Average Summary Compensation Table Total for Non-PEO NEOs		Average Compensation Actually Paid to Non-PEO NEOs			Value of Initial Fixed $100 Investment Based On:				Net Income			Total Revenue
										Total Share-holder Return		Peer Group Total Share-holder Return
	($)		($)		($)		($)			($)		($)		($ Millions)			($ Millions)
(a)	(b) (1)		(c) (2)		(d) (3)		(e) (4)			(f) (5)		(g) (6)		(h) (7)			(i) (8)
2025		6,207,000		9,488,033		2,644,420		4,032,850			50		120		(60.5	)		322.7
2024		6,128,000		4,064,580		2,237,139		1,334,343			35		91		(42.7	)		283.5
2023		5,309,167		5,035,476		1,687,019		1,715,482			55		92		(167.8	)		289.2
2022		5,233,873		3,448,273		3,829,640		(2,733,189	)		57		89		143.4			619.0
2021		5,664,303		5,664,303		758,236		6,545,715			193		99		507.4			992.6

Footnotes:

(1)

The dollar amounts reported in column (b) are the amounts of total compensation reported for Ming Hsieh, our Chief Executive Officer (our PEO), for each corresponding year in the “Total” column of the Summary Compensation Table.

(2)

The dollar amounts reported in column (c) represent the amount of compensation actually paid (“CAP”) to Mr. Hsieh, as computed in accordance with SEC rules. The dollar amounts do not reflect the actual amount of compensation earned by or paid to Mr. Hsieh during the applicable year.

In accordance with SEC rules, the following adjustments were made to Mr. Hsieh’s total compensation for each year to determine CAP:


Footnote (2) - Table 1
Year	Reported Summary Compensation Table Total for PEO		Reported Value of Equity Awards		Equity Award Adjustments		Compensation Actually Paid to PEO
	($)		($)		($)		($)
(a)	(b)		(c) (i)		(d) (ii)		(e)
2025		6,207,000		4,000,000		7,281,033		9,488,033
2024		6,128,000		4,000,000		1,936,580		4,064,580
2023		5,309,167		3,000,000		2,726,309		5,035,476
2022		5,233,873		3,572,400		1,786,800		3,448,273
2021		5,664,303		—		—		5,664,303

The grant date fair value of equity awards in column (c) of Footnote (2) - Table 1 represents the total of the amounts reported in the “Stock Awards” column in the Summary Compensation Table for the applicable year.

ii.

The equity award adjustments in column (d) of Footnote (2) - Table 1 include the addition (or subtraction, as applicable) of the following: (1) the year-end fair value of any equity awards granted in the applicable year that are outstanding and unvested as of the end of the year; (2) the amount of change as of the end of the applicable year (from the end of the prior fiscal year) in fair value of any awards granted in prior years that are outstanding and unvested as of the end of the applicable year; and (3) for awards granted in prior years that vest in the applicable year, the amount equal to the change as of the vesting date (from the end of the prior fiscal year) in fair value. The valuation assumptions used to calculate fair values did not materially differ from those disclosed at the time of grant. The amounts deducted or added in calculating the equity award adjustments are as follows:


Footnote (2) - Table 2
Year	Year End Fair Value of Equity Awards Granted During the Year that Remained Unvested		Year over Year Change in Fair Value of Equity Awards Granted in Prior Years that Remained Unvested			Fair Value as of Vesting Date of Equity Awards Granted and Vested in the Year		Year over Year Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Year			Fair Value at the End of the Prior Year of Equity Awards that Failed to Meet Vesting Conditions in the Year			Value of Dividends or other Earnings Paid on Stock or Option Awards not Otherwise Reflected in Fair Value or Total Compensation		Total Equity Award Adjustments
	($)		($)			($)		($)			($)			($)		($)
(a)	(b)		(c)			(d)		(e)			(f)			(g)		(h)
2025		6,450,572		882,788			—		(52,327	)		—			—		7,281,033
2024		3,045,334		(718,710	)		—		(390,043	)		—			—		1,936,580
2023		2,740,263		(32,625	)		—		89,667			(70,996	)		—		2,726,309
2022		1,786,800		—			—		—			—			—		1,786,800
2021		—		—			—		—			—			—		—

(3)

The dollar amounts reported in column (d) represent the average of the amounts reported for the Company’s NEOs as a group (excluding the Company’s PEO) in the “Total” column of the Summary Compensation Table in each applicable year. The names of each of the NEOs (excluding the Company’s PEO) included for purposes of calculating the average amounts in each applicable year are as follows: Paul Kim, our Chief Financial Officer, Hanlin Gao, our Chief Scientific Officer and Laboratory Director, and Jian Xie, our President and Chief Operating Officer, for 2021, 2022, 2023, 2024, and 2025.

(4)

The dollar amounts reported in column (e) represent the average amount of CAP to the NEOs as a group (excluding the Company’s PEO), as computed in accordance with SEC rules. The dollar amounts do not reflect the actual average amount of compensation earned by or paid to the NEOs as a group (excluding the Company’s PEO) during the applicable year.

In accordance with the SEC rules, the following adjustments were made to average total compensation for the NEOs as a group (excluding the Company’s PEO) for each year to determine the CAP, using the same methodology described above in Footnote 2:


Footnote (4) - Table 1
Year	Average Reported Summary Compensation Table Total for Non-PEO NEOs		Average Reported Value of Equity Awards		Average Equity Award Adjustments			Average Compensation Actually Paid to Non-PEO NEOs
	($)		($)		($)			($)
(a)	(b)		(c)		(d) (i)			(e)
2025		2,644,420		1,728,000		3,116,431			4,032,850
2024		2,237,139		1,440,000		537,204			1,334,343
2023		1,687,019		864,000		892,463			1,715,482
2022		3,829,640		3,115,000		(3,447,829	)		(2,733,189	)
2021		758,236		89,857		5,877,336			6,545,715

The amounts deducted or added in calculating the total average equity award adjustments are as follows:


Footnote (4) - Table 2
Year	Average Year End Fair Value of Equity Awards Granted During the Year that Remained Unvested		Year over Year Average Change in Fair Value of Equity Awards Granted in Prior Years that Remained Unvested			Average Fair Value as of Vesting Date of Equity Awards Granted and Vested in the Year		Year over Year Average Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Year			Average Fair Value at the End of the Prior Year of Equity Awards that Failed to Meet Vesting Conditions in the Year			Average Value of Dividends or other Earnings Paid on Stock or Option Awards not Otherwise Reflected in Fair Value or Total Compensation		Total Average Equity Award Adjustments
	($)		($)			($)		($)			($)			($)		($)
(a)	(b)		(c)			(d)		(e)			(f)			(g)		(h)
2025		2,786,652		322,319			—		7,460			—			—		3,116,431
2024		1,096,324		(299,444	)		—		(259,676	)		—			—		537,204
2023		789,185		(37,573	)		—		166,402			(25,551	)		—		892,463
2022		1,489,000		(3,304,514	)		—		(1,632,315	)		—			—		(3,447,829	)
2021		117,355		3,904,479			—		1,855,502			—			—		5,877,336

(5)

The cumulative total stockholder return (“TSR”) amounts reported in column (f) are calculated in the same manner as required under Item 201(e) of Regulation S-K, measuring the total stockholder return from the market close on the last trading day before the earliest fiscal year in the table, or December 31, 2020, through to and including the end of the fiscal year for which total stockholder return is calculated, or December 31, 2025.

(6)

The weighted peer group TSR amounts reported in column (g) reflect the Company’s peer group (NASDAQ Biotechnology Index) as reflected in our Annual Report pursuant to Item 201(e) of Regulation S-K for the fiscal year ended December 31, 2025. Each year reflects what the cumulative value of $100 would be, including the reinvestment of dividends, if such amount were invested as of market close on December 31, 2020.

(7)

The dollar amounts reported in column (h) are the Company’s net income amounts reflected in the Company’s audited financial statements for the applicable year.

(8)

While the Company uses numerous financial and non-financial performance measures for the purpose of evaluating performance for the Company’s compensation programs, the Company has determined that revenue is the financial performance measure that, in the Company’s assessment, represents the most important performance measure (that is not otherwise required to be disclosed in the Pay Versus Performance Table) used by the company to link compensation actually paid to the Company’s NEOs, for the most recently completed fiscal year, to company performance. The dollar amounts reported in column (i) are the Company’s revenue amounts reflected in the Company’s audited financial statements for the applicable year.

Company Selected Measure Name

Total Revenue

Named Executive Officers, Footnote

(1)

Peer Group Issuers, Footnote

(6)

PEO Total Compensation Amount

$ 6,207,000

$ 6,128,000

$ 5,309,167

$ 5,233,873

$ 5,664,303

PEO Actually Paid Compensation Amount

$ 9,488,033

4,064,580

5,035,476

3,448,273

5,664,303

Adjustment To PEO Compensation, Footnote

(2)

In accordance with SEC rules, the following adjustments were made to Mr. Hsieh’s total compensation for each year to determine CAP:


Footnote (2) - Table 1
Year	Reported Summary Compensation Table Total for PEO		Reported Value of Equity Awards		Equity Award Adjustments		Compensation Actually Paid to PEO
	($)		($)		($)		($)
(a)	(b)		(c) (i)		(d) (ii)		(e)
2025		6,207,000		4,000,000		7,281,033		9,488,033
2024		6,128,000		4,000,000		1,936,580		4,064,580
2023		5,309,167		3,000,000		2,726,309		5,035,476
2022		5,233,873		3,572,400		1,786,800		3,448,273
2021		5,664,303		—		—		5,664,303

ii.


Footnote (2) - Table 2
Year	Year End Fair Value of Equity Awards Granted During the Year that Remained Unvested		Year over Year Change in Fair Value of Equity Awards Granted in Prior Years that Remained Unvested			Fair Value as of Vesting Date of Equity Awards Granted and Vested in the Year		Year over Year Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Year			Fair Value at the End of the Prior Year of Equity Awards that Failed to Meet Vesting Conditions in the Year			Value of Dividends or other Earnings Paid on Stock or Option Awards not Otherwise Reflected in Fair Value or Total Compensation		Total Equity Award Adjustments
	($)		($)			($)		($)			($)			($)		($)
(a)	(b)		(c)			(d)		(e)			(f)			(g)		(h)
2025		6,450,572		882,788			—		(52,327	)		—			—		7,281,033
2024		3,045,334		(718,710	)		—		(390,043	)		—			—		1,936,580
2023		2,740,263		(32,625	)		—		89,667			(70,996	)		—		2,726,309
2022		1,786,800		—			—		—			—			—		1,786,800
2021		—		—			—		—			—			—		—

Non-PEO NEO Average Total Compensation Amount

$ 2,644,420

2,237,139

1,687,019

3,829,640

758,236

Non-PEO NEO Average Compensation Actually Paid Amount

$ 4,032,850

1,334,343

1,715,482

(2,733,189)

6,545,715

Adjustment to Non-PEO NEO Compensation Footnote

(4)


Footnote (4) - Table 1
Year	Average Reported Summary Compensation Table Total for Non-PEO NEOs		Average Reported Value of Equity Awards		Average Equity Award Adjustments			Average Compensation Actually Paid to Non-PEO NEOs
	($)		($)		($)			($)
(a)	(b)		(c)		(d) (i)			(e)
2025		2,644,420		1,728,000		3,116,431			4,032,850
2024		2,237,139		1,440,000		537,204			1,334,343
2023		1,687,019		864,000		892,463			1,715,482
2022		3,829,640		3,115,000		(3,447,829	)		(2,733,189	)
2021		758,236		89,857		5,877,336			6,545,715

The amounts deducted or added in calculating the total average equity award adjustments are as follows:


Footnote (4) - Table 2
Year	Average Year End Fair Value of Equity Awards Granted During the Year that Remained Unvested		Year over Year Average Change in Fair Value of Equity Awards Granted in Prior Years that Remained Unvested			Average Fair Value as of Vesting Date of Equity Awards Granted and Vested in the Year		Year over Year Average Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Year			Average Fair Value at the End of the Prior Year of Equity Awards that Failed to Meet Vesting Conditions in the Year			Average Value of Dividends or other Earnings Paid on Stock or Option Awards not Otherwise Reflected in Fair Value or Total Compensation		Total Average Equity Award Adjustments
	($)		($)			($)		($)			($)			($)		($)
(a)	(b)		(c)			(d)		(e)			(f)			(g)		(h)
2025		2,786,652		322,319			—		7,460			—			—		3,116,431
2024		1,096,324		(299,444	)		—		(259,676	)		—			—		537,204
2023		789,185		(37,573	)		—		166,402			(25,551	)		—		892,463
2022		1,489,000		(3,304,514	)		—		(1,632,315	)		—			—		(3,447,829	)
2021		117,355		3,904,479			—		1,855,502			—			—		5,877,336

Compensation Actually Paid vs. Total Shareholder Return

Compensation Actually Paid vs. Company Selected Measure

Total Shareholder Return Vs Peer Group

The following graph compares our cumulative TSR over the five most recently completed fiscal years to that of the NASDAQ Biotechnology Index (“Index”) over the same period.

Tabular List, Table

The most important financial performance measures used by the Company to link executive compensation actually paid to the Company’s NEOs, for the most recently completed fiscal year, to the Company’s performance are as follows:

(1)

Revenue

(2)

EBITDA

(3)

Total Stockholder Return

(4)

Earnings Per Share

(5)

Adjusted EBITDA (1)

(1)

Adjusted EBITDA is GAAP income (loss) plus or minus interest (expense) income, plus or minus provisions (benefits) for income taxes, plus goodwill impairment loss, plus acquisition-related costs, plus equity-based compensation expenses, plus depreciation and amortization, plus impairment loss of investments, plus insurance expense related to transferable tax credits, plus one-time professional liability expense, and plus or minus other charges or gains, as identified, that management believes are not representative of the Company’s operations.

Total Shareholder Return Amount

$ 50

193

Peer Group Total Shareholder Return Amount

120

Net Income (Loss)

$ (60,500,000)

$ (42,700,000)

$ (167,800,000)

$ 143,400,000

$ 507,400,000

Company Selected Measure Amount

322,700,000

283,500,000

289,200,000

619,000,000

992,600,000

PEO Name

Ming Hsieh